Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Medtronic Bakken Research Center |
---|---|
Information provided by: | Medtronic Bakken Research Center |
ClinicalTrials.gov Identifier: | NCT00147277 |
The purpose of this study is to estimate and quantify the difference in efficacy of two sequences of ATP therapies (burst 15 pulses, 88% versus burst 8 pulses, 88%) during an episode of spontaneous rhythms classified as fast ventricular tachycardia (FVT) via ventricular fibrillation (VF) in patients who have a Class I or II A indication for ICD implantation, and thus to promote the "painless" therapy aspect of ICD treatment and improve quality of life outcomes for patients.
Condition | Intervention | Phase |
---|---|---|
Tachycardia, Ventricular Ventricular Fibrillation |
Device: Implantable Cardiac Defibrillator |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Subject), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | ADVANCE-D: ATP Delivery for Painless ICD Therapy |
Enrollment: | 925 |
Study Start Date: | March 2004 |
Study Completion Date: | January 2008 |
Primary Completion Date: | January 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
8 pulses: Active Comparator
8 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)
|
Device: Implantable Cardiac Defibrillator
Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
|
15 pulses: Experimental
15 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)
|
Device: Implantable Cardiac Defibrillator
Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
|
Main objective: Compare & quantify efficacy of two different sequences of burst ATP strategies for the termination of ventricular tachycardia (with Cycle Lenght (CL) of 240ms-320ms) from baseline to 12 months post randomisation in patients who are treated with ATP -8 pulses, 88% versus patients who are treated with ATP -15 pulses, 88%
Secondary objectives:
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Italy, MI | |
Medtronic Italia SpA | |
Sesto San Giovanni, MI, Italy, 20099 |
Principal Investigator: | Maurizio Lunati, Dr. | Ospedale Niguarda Cà Granda - Milano |
Principal Investigator: | Riccardo Cappato, Dr. | Istituto Policlinico S. Donato Milanese |
Principal Investigator: | Massimo Santini, Prof. | San Filippo Neri - Roma |
Principal Investigator: | Angel Arenal, Dr. | Hospital Gregorio Marañón - Madrid |
Principal Investigator: | Josè Luis Merino, Dr. | Hospital La Paz - Madrid |
Principal Investigator: | Arcadio Garcia-Alberola, Dr. | Hospital Virgen de la Arrixaca - Murcia |
Principal Investigator: | Johann Mermi, Dr. | Clinic Center Dortmund |
Principal Investigator: | Pascal Defaye, Dr. | University Hospital, Grenoble |
Study ID Numbers: | 900AD |
Study First Received: | September 6, 2005 |
Results First Received: | November 20, 2008 |
Last Updated: | June 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00147277 History of Changes |
Health Authority: | Italy: Ministry of Health |
ATP Thachy FVT |
Paroxysmal Ventricular Fibrillation Heart Diseases Tachycardia |
Tachycardia, Ventricular Ventricular Fibrillation Arrhythmias, Cardiac |
Pathologic Processes Heart Diseases Tachycardia Cardiovascular Diseases |
Tachycardia, Ventricular Ventricular Fibrillation Arrhythmias, Cardiac |